BEIJING, Dec. 9, 2010 /PRNewswire-Asia-FirstCall/ -- Lotus
Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the
"Company"), a fast-growing, profitable developer, manufacturer and
seller of medicine and drugs in the
People's Republic of China ("PRC"), announced today that it
will participate in PHARMCHINA's 64th National Drug Fair
Conference, to be held December 9-11,
2010 at the Nanchang International Exhibition Center in
Nanchang, Jiangxi Province, PRC.
More than 100,000 visitors are expected to attend PHARMCHINA,
the largest exhibition in the Chinese pharmaceutical industry.
Lotus' operating entity, Liang Fang Pharmaceutical, Ltd., will
exhibit its product offerings at Booth #203 during the event.
Chairman and Chief Executive Officer Mr. Zhongyi Liu stated, "PHARMCHINA provides us with
a valuable opportunity to increase awareness of our self-branded
and third-party distributed pharmaceutical products. At this event,
we intend to seek new distribution channels and business partners
to strengthen our national sales network and grow our market share.
We will also seek out pharmaceutical products that we can begin
distributing to our growing customer base, as well as innovative
development-stage products for potential acquisition."
About Lotus Pharmaceuticals, Inc.
Lotus Pharmaceuticals, Inc. is a fast-growing, profitable
developer and producer of drugs and a licensed national seller of
pharmaceutical items in the People's
Republic of China (PRC). Lotus operates its business through
its two controlled entities: Liang Fang Pharmaceutical, Ltd. and En
Ze Jia Shi Pharmaceutical, Ltd. Lotus' current drug development is
focused on the treatment of cerebro-cardiovascular diseases, asthma
and diabetes. Liang Fang sells drugs
directly and indirectly through its national sales channels to
hospitals, clinics and drugs stores in 30 provinces of the PRC.
Information Regarding Forward-Looking Statements
Except for historical information contained herein, the
statements in this press release are forward-looking statements
that are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements involve known and unknown risks and uncertainties, which
may cause our actual results in future periods to differ materially
from forecasted results. These risks and uncertainties include,
among other things, product demand, market competition, and risks
inherent in our operations. These and other risks are described in
our filings with the U.S. Securities and Exchange
Commission.
Contacts:
|
|
|
|
At the Company:
|
|
Xing Shen, Ph.D.
|
|
VP of Corporate
Development
|
|
Lotus Pharmaceuticals,
Inc.
|
|
Tel: +1-415-690-7688
|
|
Email:
shen@lotuspharma.com
|
|
Web:
http://www.lotuspharma.com
|
|
|
|
Investor
Relations:
|
|
Dave Gentry
|
|
RedChip Companies,
Inc.
|
|
Tel: +1-800-733-2447, Ext.
104
|
|
Email:
info@redchip.com
|
|
Web:
http://www.redchip.com
|
|
|
SOURCE Lotus Pharmaceuticals, Inc.